Sight Sciences Reports Second Quarter 2026 Financial Results
Sight Sciences reported Q2 revenue of $23.4 million, up 20% year-over-year, driven by an 8% increase in Interventional Glaucoma revenue and a 704% surge in Interventional Dry Eye revenue. The company raised its full-year 2026 revenue guidance to $88 million to $92 million, up from a prior range of $83 million to $89 million, while simultaneously lowering its adjusted operating expense guidance.
Key figures
- Revenue
- 23400000
- Guidance
- FY26 revenue raised to $88M-$92M vs prior $83M-$89M; Adjusted OpEx reduced to $92M-$94M vs prior $93M-$96M
- Revenue Yoy
- 0.2
- Cash
- $79.8 million
- Ig revenue
- $20.7 million
- Ide revenue
- $2.7 million
- Gross margin
- 91%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.